PSAT1 and ovarian cancer: A study has demonstrated that upregulation of miR-195-5p declines angiogenesis and cisplatin resistance in ovarian cancer via suppressing the phosphoserine aminotransferase 1 (PSAT1)-dependent GSK3β/β-catenin signaling pathway [10].